Skip to main content

Table 1 Patient characteristics

From: Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy

Patient demographics

Variables

Value

Sex

Male/female

8/3

Age

Median/range

64.0/43–78

Tumor depth

cT4/T3/T2

6/4/1

Nodal stage

cN3/N2/N1

5/5/1

Hepatic metastasis

Positive/negative

6/5

Distant metastasis (except liver)

Positive/negative

5/6

Peritoneal metastasis

P1/P0 and CY1/P0

2/3/6

Regimen

XPT/SPT

9/2

  1. P1 peritoneal metastasis, CY peritoneal cytology, XPT xeloda + cisplatin + trastuzumab, SPT S-1 + cisplatin + trastuzumab